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The main side effect of the chronic application of re-
combinant human erythropoietin (rHuEPO) as therapy
for patients who receive hemodialysis has been reported
to be the development or aggravation of hypertension,
which can be explained only partially by an increase in
blood viscosity,1 a diminished hypoxic vasodilatation, or
an enhanced cardiac output that is caused by a better
level of myocardial oxygenation.2 The development of
hypertension directly after the application suggested that
other pressor mechanisms may be involved.3 The direct
vasoconstrictor effect of erythropoietin has been re-
ported by various authors in animal studies,4,5 but we
have found no data in the literature on the direct effect
of erythropoietin on human placental blood vessels. The
placental transfer of erythropoietin in humans seems
quite unlikely,6 but the human placenta7 and the fetal
liver, kidney, spleen, and bone marrow8 produce erythro-
poietin during pregnancy. The erythropoietin receptor
protein and messenger RNA, classically found in ery-
throid precursor cells,9 have been described in other cell
types, including endothelial cells of the fetoplacental vas-
culature.10 These novel and nonclassic sites of erythro-
poietin and erythropoietin-receptor expression raise the
possibility of physiologic roles for this hormone that are
not related necessarily to erythropoiesis. Thus, the direct
effects of rHuEPO on isolated human placental blood
vessels were examined.
Considerable interest has focused recently on the po-
tential for angiotensin-converting enzyme inhibitors and
angiotensin II receptor antagonists to affect the response
to erythropoietin.11 The conractile effect on the rat
mesenteric artery can be abolished by losartan (a selec-
tive antagonist of angiotensin II type 1 receptor [AT1 re-
ceptor]) but cannot be blunted by captopril (an
angiotensin-converting enzyme inhibitor).4 In the cur-
rent study, the effects of captopril and losartan on the
rHuEPO-induced contractions of isolated human placen-
tal veins and arteries were also investigated.
Material and methods
Placentas were obtained from the delivery room of
the Department of Obstetrics and Gynecology of the
university immediately after the birth; they were trans-
ferred in 500 mL of icy Krebs-Henseleit buffer (118
mmol/L sodium chloride, 5 mmol/L potassium chlo-
ride, 2 mmol/L calcium chloride, 0.5 mmol/L magne-
sium sulfate, 1 mmol/L potassium sulfate, 25 mmol/L
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OBJECTIVE: The aim of this study was to investigate the direct effect of erythropoietin on human placental
vessels.
STUDY DESIGN: Placental vessel rings (n = 8 for each group) from uncomplicated pregnancies were ex-
posed to recombinant human erythropoietin (10-300 IU/mL) in an isometric myograph. One-way analysis of
variance with the Bonferroni posttest was used to evaluate significant levels of differences.
RESULTS: Recombinant human erythropoietin evoked reproducible contractions on the vessel rings in a
dose-dependent way, which were marked significantly more on veins than on arteries. These contractile re-
sponses were not changed by captopril (10–5 mol/L) but were blunted significantly by losartan (10–5 mol/L).
CONCLUSION: We concluded that recombinant human erythropoietin exerts a direct contractile effect on
human placental vessels, angiotensin II type 1 receptors are needed to mediate these responses, and ery-
thropoietin might participate in one of the humoral mechanisms that are involved in the control of the human
placental vascular bed and also in the pathogenesis of intrauterine growth restriction and preeclampsia.
(Am J Obstet Gynecol 2003;188:993-6.)
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sodium bicarbonate, 10 mmol/L glucose; pH-7.4); the
experiments were begun 10 to 30 minutes after the
birth. All the placentas originated from term pregnan-
cies that ended with uncomplicated deliveries. The ages
of the women from whom the placentas were obtained
ranged between 19 and 28 years, with an average of 25.3
years. The gestational age at delivery was between 37
and 40 weeks, with an average of 38.1 weeks of gestation.
After the umbilical cord had been cut off, thin polyeth-
ylene cannulas were led into the vein (with larger diam-
eter) and the two arteries (with smaller diameters) in
the stub, to separate the veins and arteries on the fetal
surface of the placenta. The vessels were prepared for in
vitro measurement according to the method outlined by
Angus and Wright.12 Rings that were 1 to 1.3 mm in di-
ameter were dissected free from the identified veins and
arteries just before they head towards the stem villi.
Small-diameter resistance vessels, compared with con-
duit vessels, contribute more to the hemodynamics of
placental bed perfusion, although the question of the
location and the diameter of resistance vessels is un-
solved, in general, and the feed arteries can be as active
in blood flow control as the microvasculature.13 The
precise length of the rings (4 mm) was achieved by the
use of a fixed double-bladed scalpel. The loose connec-
tive tissue was removed carefully under a cool fiber optic
light source and binocular dissection microscope (mag-
nification, 10). The rings were taken distally from the
site of introduction of the cannulas; the endothelium
therefore remained intact.
The rings were mounted diametrically (as ring prepa-
rations) between two stainless steel wire hooks in the
organ bath of an isometric myograph that contained 10
mL of Krebs-Henseleit buffer. The organ bath was main-
tained at 37°C and carbogen gas (95% oxygen + 5% car-
bon dioxide) was bubbled through it. After being
mounted, the rings were equilibrated for 90 minutes be-
fore the experiment, and the buffer was changed every 10
minutes. The passive force was set at approximately 3.75
g and approximately 3.25 g for veins and arteries, respec-
tively. The optimal degree of stretch was ascertained by a
determination of a contraction versus passive force curve
in response to a dose of 200 IU/mL of rHuEPO.4
The force of the vessel rings was measured with a gauge
transducer (SG-02; Experimetria Ltd, London, UK), and
was recorded by an ISOSYS Data Acquisition System (Ex-
perimetria Ltd). At our setting the passive force at the
end of equlibration is termed the base tone. Each contrac-
tile response was measured as the difference between the
top of the contraction curve and the base tone.
Measured points were plotted; curves were fitted to
these points, and the data were statistically analyzed with
Prism 2.01 software (GraphPad Software, San Diego,
Calif). One-way analysis of variance with the Bonferroni
posttest was used in all cases to evaluate the significance
Figure. a, Semilogarithmic dose-response curve of rHuEPO for
contractility of human placental veins and effects of captopril and
losartan on contractions of human placental veins elicited by
rHuEPO. rHuEPO evoked reproducible contractions in human
placental veins in a significant and dose-dependent way. At all ap-
plied doses, effect of rHuEPO on placental veins was marked
more significantly, compared with that on arteries. Incubation of
vessel rings with captopril (10–5 mol/L) did not affect their con-
tractile response to rHuEPO. In contrast, losartan at a concentra-
tion of 10–5 mol/L completely abolished contractile responses of
vessel rings at 10 IU/mL rHuEPO and significantly blunted those
responses at 300 IU/mL rHuEPO. Closed squares, Human placen-
tal veins + rHuEPO (n = 8); closed inverted triangles, human pla-
cental veins + rHuEPO + captopril (n = 8); closed triangles, human
placental veins + rHuEPO + losartan (n = 8). b, Semilogarithmic
dose-response curve of rHuEPO for contractility of human pla-
cental arteries and effects of captopril and losartan on contrac-
tions of human placental arteries elicited by rHuEPO. rHuEPO
evoked reproducible contractions in human placental arteries in
a significant and dose-dependent way. Incubation of vessel rings
with captopril (10–5 mol/L) did not affect their contractile re-
sponse to rHuEPO. In contrast, losartan at a concentration of
10–5 mol/L completely abolished contractile responses of vessel
rings at 10 IU/mL rHuEPO and significantly blunted those re-
sponses at 300 IU/mL rHuEPO. Closed squares, Human placental
arteries + rHuEPO (n = 8); closed inverted triangles, human placen-
tal arteries + rHuEPO + captopril (n = 8); closed triangles, human
placental arteries + rHuEPO + losartan (n = 8).
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levels of differences. Probability values that were lower
than .05 were considered statistically significant.
Doses of rHuEPO (LaRoche, Budapest, Hungary) that
ranged between 10 and 300 IU/mL were administered in
a cumulative way. Each dose was given when the previous
dose had exerted its maximal effect (within 2-10 min-
utes). Captopril (Sigma-Aldrich Ltd, Budapest, Hungary)
and losartan (Merck Sharp & Dohme, Budapest, Hun-
gary) were administered in a concentration of 10–5
mol/L 10 minutes before the first dose of rHuEPO.
Experimentation on human placentas has been ap-
proved by the local institution. Institutional review board
approval was obtained May 9, 2000.
Results
rHuEPO evoked reproducible contractions in human
placental blood vessel rings in a significant and dose-de-
pendent way. At all applied doses, the effect of rHuEPO
on the placental veins was marked more significantly
compared with that on the arteries.
The vasocontractions in the case of the 10 IU/mL were
0.21 ± 0.03469 g and 0.05273 ± 0.01415 g for human pla-
cental veins and arteries, respectively. At the 300 IU/mL
dose, the contractions were 1.088 ± 0.1296 g and 0.4509 ±
0.05017 g for the veins and arteries, respectively.
Incubation of the vessel rings with captopril (10–5
mol/L) did not affect the contractile response to
rHuEPO. In contrast, losartan, at a concentration of 10–5
mol/L, completely abolished the contractile responses of
the vessel rings at 10 IU/mL rHuEPO and significantly
blunted them at 300 IU/mL rHuEPO (0.11 ± 0.01528 g
and 0.1575 ± 0.03119 g for veins and arteries, respectively,
Figure).
Comment
In the current study, rHuEPO was found to have a di-
rect and dose-dependent contractile effect on human
placental blood vessels in vitro. Because the fetoplacental
vasculature lacks autonomic innervation,14 the control of
this vascular bed must involve humoral mechanisms; ery-
thropoietin might participate in one of these mecha-
nisms. To the best of our knowledge, the direct
vasopressor effect of erythropoietin on human placental
blood vessels has not been investigated yet. At all applied
doses, the contractions that were elicited by erythropoi-
etin were marked more significantly on veins than on ar-
teries. These functional results confirmed the
morphologic properties of the walls of the placental veins
and arteries. The tunica media, which contains the force-
producing smooth muscle cells, is thicker in placental
veins than in arteries.15 The contractile effect of rHuEPO
on human placental blood vessels was abolished by losar-
tan but was not blunted by captopril. Thus, it may be con-
cluded that AT1 receptors are needed to mediate the
contractile response of human placental blood vessels to
rHuEPO. There is a theoretic basis for this effect in view
of the known close links between the renin-angiotensin
system and erythropoiesis. It has been known for some
time that the renin-angiotensin system is linked intri-
cately with the production of endogenous erythropoietin
in the peritubular fibroblasts of the kidney.11 Addition-
ally, renin substrate (angiotensinogen) has chemical sim-
ilarities to erythropoietin.16 All the components of the
renin-angiotensin system have been shown to be present
in the human term placenta.17 The human term placenta
contains predominantly AT1 receptors with low levels of
AT2 receptors.18 When placental membrane preparations
were used, the AT2 receptor antagonist PD123177 failed
to compete for [3H] angiotensin II binding at relevant
concentrations, whereas the AT1-receptor antagonist
losartan competed in a monophasic manner.19 Specific
receptor binding sites for angiotensin II have also been
identified in placental vascular smooth muscle cells.20
Other experiments with the AT1-receptor–selective an-
tagonist losartan indicate that this subtype is responsible
for most of the hemodynamic and cardiovascular effects
of angiotensin II.21 In the rat, rHuEPO exerts its primary
action on vascular smooth muscle cells through an in-
crease in angiotensin-receptor messenger RNA, which re-
sults in a parallel increase in angiotensin II receptor
expression.22
The elucidation of these potential erythropoietin bind-
ing sites and the potential transport of erythropoietin
across the placental barrier23 are of clinical significance,
concerning the assessment of the safety to the fetus of
rHuEPO administration to anemic pregnant women.
However, cases have been presented in which no mater-
nal and perinatal complications that were attributable to
rHuEPO were registered.24 Because AT1 receptor activa-
tion may play a role in preeclampsia25 and AT1 receptor
expression is reduced in intrauterine growth restric-
tion,19 erythropoietin might also be involved, in part, in
the pathogenesis of these disorders.
Our durrent findings add to the growing list of non-
hematopoietic roles of erythropoietin during human de-
velopment.
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